Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.34
-0.43 (-6.35%)
At close: Nov 19, 2026, 4:00 PM EST
6.26
-0.08 (-1.34%)
After-hours: Nov 19, 2026, 7:30 PM EST
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $1.22M in the quarter ending September 30, 2026, a decrease of -64.55%. This brings the company's total for the last twelve months to $3.97M, down -97.39% year-over-year. In the year 2025, Atara Biotherapeutics had annual revenue of $120.77M, down -6.33%. That makes Atara Biotherapeutics the 40,718th largest company in the world by revenue and 5,443rd in the United States.
Revenue (ttm)
$3.97M
Revenue Growth
-97.39%
P/S Ratio
16.21
Revenue / Employee
$396,500
Employees
10
Market Cap
64.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 120.77M | -8.17M | -6.33% |
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 78.42M |
| Champions Oncology | 60.66M |
| NeurAxis | 6.53M |
| Nutriband | 1.62M |
| MediciNova | 935.72K |
| Cardiff Oncology | 559.00K |
ATRA News
- 9 days ago - Atara Biotherapeutics files $200M mixed securities shelf - TheFly
- 9 days ago - Atara Biotherapeutics reports Q3 EPS (15c), consensus (22c) - TheFly
- 9 days ago - Atara Biotherapeutics says cash sufficient to fund operations into mid-2027 - TheFly
- 9 days ago - Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress - Business Wire
- 9 days ago - Atara Biotherapeutics Earnings release: Q3 2026 - Filings
- 9 days ago - Atara Biotherapeutics Quarterly report: Q3 2026 - Filings
- 9 days ago - Atara Biotherapeutics Registration statement: Registration filing - Filings
- 5 weeks ago - Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel - TheFly